The upgrade from JP Morgan is a positive signal for Editas Medicine. It indicates that the analyst sees potential in the company's stock, which could lead to increased investor interest and potentially a rise in the stock price. The new price target of $8 also suggests that the analyst believes the stock is undervalued at its current price.